Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social care, in conversation with In Vivo.

Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.

Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.

Merck said the Phase III study of the combination in non-small cell lung cancer did not meet its dual primary endpoint of overall survival and progression-free survival.